Midatech is fully focussed on enhancing and extending the lives of patients with rare and serious cancers. We have built an organization distinguished by world-class scientists with a talent for developing and applying our novel drug delivery technologies to improve existing, or develop new, treatments for these diseases. Our driving philosophy is to seize scientific and clinical opportunities and invest in programmes and partnerships to get these treatments to approval and commercialisation.
Midatech Pharma is focused on the research and development of medicines for rare cancers, via both in house programmes as well as partnered programmes. We develop improved chemo~therapeutics or new immuno~therapeutics, using our proprietary platform drug delivery technologies.
All our technologies are thus focussed on improved bio-delivery and bio-distribution of medicines or agents to areas of the body where they are needed and can exert their actions in an effective, safe and precise manner.
In this way Midatech’s objective is to address lethal diseases that otherwise may not be possible, or very difficult.
Our blueprint for success in the years ahead is inspired by developing and advancing our treatments and platform technologies, via in house programmes as well as in collaboration with partners, that will make a difference for patients and healthcare workers, and create value for payers, and our shareholders.